Publication | Closed Access
Haplotype-specific suppression of experimental allergic encephalomyelitis with anti-IA antibodies.
41
Citations
0
References
1987
Year
HistocompatibilityAllergy MedicineImmunologyPathologyImmunodominanceAntigen ProcessingImmunotherapyHaplotype-specific SuppressionImmunogeneticsAutoantibodiesNeuroimmunologyCell TransplantationMonoclonal AntibodyAllergyAutoimmune DiseaseAutoimmunityHumoral ImmunityImmunologic DiseasePassive TransferInborn Error Of ImmunityImmunomodulationImmunoglobulin EMonoclonal AntibodiesMedicine
Treatment with monoclonal antibodies directed against the IA antigens of the MHC is known to alter the course and prevent a number of experimental autoimmune diseases. To determine whether the treatment in vivo with anti-IA antibodies is haplotype-specific, we studied the development of EAE in F1 (SJL/J X BALB/c) mice following anti-IA antibody therapy. We report that treatment of animals with monoclonal antibody directed against the high responder allele product, I-As, was successful in preventing disease when therapy was begun either at the time of immunization with antigen, or following passive transfer of MBP-sensitized T cells. Therapy with antibody directed to the low responder allele product (I-Ad), while effective when used at the time of immunization with antigen, was ineffective following passive transfer of MBP-sensitized lymphocytes.